Meta‐analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients

Fabrizi, F.; Dixit, Vivek; Martin, Paul

doi:10.1111/j.1365-2036.2010.04410.x

Cited by 35 publications

(36 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levamisole, a synthetic phenylimidazolthiazole with an antihelminthic effect, has been reported to stimulate depressed T-cell activity and enhance the production of antibodies by B cells (7475). In addition, Chen et al demonstrated that the treatment of monocyte-derived DCs from healthy donors with levamisole increased the presentation of CD80, CD86, CD83 and MHC class II molecules on the cell membrane and the production of IL-12 p40.…”

Section: Modulation Of DC Function In Patients With Esrdmentioning

confidence: 99%

“…Moreover, a meta-analysis of four studies (328 patients) showed that the oral administration of levamisole at a dose of 80~120 mg for 4~6 months significantly increased seroconversion after HBV vaccination (75). These observations suggest that levamisole could significantly improve the response rates of patients on HD to several vaccines through, at least in part, activating DCs.…”

Section: Modulation Of DC Function In Patients With Esrdmentioning

confidence: 99%

See 1 more Smart Citation

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

Kim

et al. 2017

Immune Netw

View full text Add to dashboard Cite

End-stage renal disease (ESRD) with immune disorder involves complex interactions between the innate and adaptive immune responses. ESRD is associated with various alterations in immune function such as a reduction in polymorphonuclear leukocyte bactericidal activity, a suppression of lymphocyte proliferative response to stimuli, and a malfunction of cell-mediated immunity at the molecular level. ESRD also increases patients' propensity for infections and malignancies as well as causing a diminished response to vaccination. Several factors influence the immunodeficiency in patients with ESRD, including uremic toxins, malnutrition, chronic inflammation, and the therapeutic dialysis modality. The alteration of T-cell function in ESRD has been considered to be a major factor underlying the impaired adaptive cellular immunity in these patients. However, cumulative evidence has suggested that the immune defect in ESRD can be caused by an Ag-presenting dendritic cell (DC) dysfunction in addition to a T-cell defect. It has been reported that ESRD has a deleterious effect on DCs both in terms of their number and function, although the precise mechanism by which DC function becomes altered in these patients is unclear. In this review, we discuss the effects of ESRD on the number and function of DCs and propose a possible molecular mechanism for DC dysfunction. We also address therapeutic approaches to improve immune function by optimally activating DCs in patients with ESRD.

show abstract

Section: Modulation Of DC Function In Patients With Esrdmentioning

confidence: 99%

Section: Modulation Of DC Function In Patients With Esrdmentioning

confidence: 99%

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

Kim

et al. 2017

Immune Netw

View full text Add to dashboard Cite

show abstract

“…Most of the published systematic reviews on this subject have been performed by Fabrizi et al [31] investigating potential effects of a large number of factors on HBV vaccination in dialysis patients. For example they found no significant effects for using erythropoetin (Epo) [31] and some other adjuvants [32] on the immunogeneity of HB vaccination in kidney disease patients; while several other factors significantly associated with seroconversion have also been reported by the same authors that included use of levamisole [33] , granulocyte macrophage-colony stimulating factor [32] and thymopentin use [34] . Seroresponse of patients on maintenance hemodialysis vs peritoneal dialysis …”

Section: Discussionmentioning

confidence: 90%

Sex bias in response to hepatitis B vaccination in end-stage renal disease patients: Meta-analysis

Khedmat

Aghaei

Ghamar-Chehreh

et al. 2016

WJN

View full text Add to dashboard Cite

AIM:To systematically review the literature for studies investigating the potential effect of gender of dialysis patients on the immunogenicity of hepatitis B virus vaccines. METHODS:Literature searches were conducted by the MEDLINE and Google Scholar. The key words used included "hepatitis B (HB)", "vaccine", "dialysis", "hemodialysis", "sex", "male" and "female". Data of seroresponse to HB vaccine in clinical trials regarding sex of the recipients have been achieved and analyzed. Finally data from 19 clinical trials have been pooled and analyzed. RESULTS:Analysis of response to HB vaccination in our dialysis population showed males significantly respond less to hepatitis B vaccination (P = 0.002, Z = 3.08) with no significant heterogeneity detected [P = 0.766; heterogeneity χ 2 = 14.30 (df = 19); I 2 = 0%]. A reanalysis of the pooled data was conducted regarding the dialysis mode to evaluate potential differential impact of sex on HB vaccine response. Hemodialysis was the only subgroup that showed a significant difference regarding dialysis mode in response to HB vaccination regarding sex (P = 0.042, Z = 2.03). CONCLUSION:This Meta-analysis showed significant effect for the sex of chronic kidney disease and dialysis patients on the immunogenicity of HB vaccine. This sex discrimination was most prominent among hemodialysis patients.

show abstract

“…2), in the literature, have been considered to be adaptogens. Dibazol’s adaptogenic action was first realized in the context of immune-mechanism-enabled adaptation to difficult environmental conditions (Rusin, 1962a, 1962b, 1963a, 1963b, 1963c, 1967; Ratnikov and Nesterenko, 1984; Novikov and Bortnovskii, 1985; Udintsev et al ., 1991; Sidorova and Kiikova, 2000); levamisole’s adaptogenic activity also is connected primarily with adaptive immune system changes (Voskanian et al ., 1986; Alvarez-Pellitero et al ., 2006; Chen et al ., 2008; Fabrizi et al ., 2010); afobazol has neuroprotective properties established, in vitro , by survival of HT-22 neurons in a model of oxidative stress and glutamate toxicity (Zenina et al ., 2005), and its adaptogenic action is realized through central nervous system adaptation (Uyanaev and Fisenko, 2006; Litvintsev et al ., 2007; Bogdan et al ., 2011). As reflects their adaptogenic properties, benzimidazole derivatives are related to bemitil, but their influence on physical work capacity is either absent or minimal.…”

Section: Definition and Classification Of Actoprotectorsmentioning

confidence: 99%

The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance

Oliynyk¹,

Oh²

2012

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Actoprotectors are preparations that enhance body stability against physical loads without increasing oxygen consumption or heat production. Or, in short, actoprotectors are synthetic adaptogens with a significant capacity to improve physical performance. This paper explores the history of actoprotectors’development, their pharmacological properties, mechanism of action, and practical application to the improvement of mental and physical performance. A brief summary of the clinico-pharmacological characteristics of the main representatives of this class (bemitil and bromantane) is provided. Some other synthesized compounds, and even natural ones such as ginseng, also are regarded as potential actoprotectors, and these are treated herein as well. Actoprotectors, owing to their wide-ranging pharmacological activities, high efficiency and safety, can be applied under either normal or extreme conditions.

show abstract

Meta‐analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients

Cited by 35 publications

References 42 publications

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

Sex bias in response to hepatitis B vaccination in end-stage renal disease patients: Meta-analysis

The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance

Contact Info

Product

Resources

About